论文部分内容阅读
目的:观察舒肝益脾颗粒联合阿德福韦酯(Adefovir Dipivoxil,ADV)治疗慢性乙型肝炎(Chronic Hepatitis B,CHB)的效果。方法:将CHB患者随机分为对照组和观察组,对照组给予阿德福韦酯胶囊,观察组在对照组的基础上加用舒肝益脾颗粒,疗程为48周。比较两组的丙氨酸转氨酶(Alanine Aminotransferase,ALT)、乙肝e抗原(Hepatitis B Virus e Antigen,HBeAg)和乙肝病毒脱氧核糖核酸(Hepatitis B Virus Deoxyribonucleic Acid,HBV-DNA)转阴率。结果:观察组的ALT、HBeAg和HBV-DNA转阴率明显高于对照组,两组均无明显不良反应,值得临床推广应用。结论:舒肝益脾颗粒联合ADV治疗CHB安全有效,值得临床推广应用。
Objective: To observe the effect of Shugan Yipi granule combined with Adefovir Dipivoxil (ADV) in the treatment of Chronic Hepatitis B (CHB). Methods: CHB patients were randomly divided into control group and observation group. The control group was given adefovir dipivoxil capsule. The observation group was treated with Shugan Yipi granulation on the basis of the control group for 48 weeks. Alanine Aminotransferase (ALT), Hepatitis B Virus e Antigen (HBeAg) and Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) were compared between the two groups. Results: The ALT, HBeAg and HBV-DNA negative rates in observation group were significantly higher than those in control group. There was no obvious adverse reactions in both groups, which deserved clinical application. Conclusion: Shugan Yipi granule combined with ADV in the treatment of CHB is safe and effective, which is worthy of clinical application.